Industry
Biotechnology
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Loading...
Open
1.08
Mkt cap
43M
Volume
206K
High
1.09
P/E Ratio
-0.62
52-wk high
3.16
Low
1.03
Div yield
N/A
52-wk low
0.80
Portfolio Pulse from
November 07, 2024 | 12:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 1:15 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 11:33 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 4:59 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
July 02, 2024 | 8:47 pm
Portfolio Pulse from Vaishali Prayag
June 28, 2024 | 5:59 pm
Portfolio Pulse from ryanfaloona@benzinga.com
June 28, 2024 | 12:37 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.